Retaspimycin Hydrochloride — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	10	—	—	2005-06
Malignant Breast Neoplasm	Phase2	Phase 2	2	—	—	2008-04
Malignant Lung Neoplasm	Phase2	Phase 2	3	—	—	2007-01
Malignant Prostate Neoplasm	Phase2	Phase 2	1	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ALK Fusion1
Crizotinib + Retaspimycin Hydrochloride

Clinical trials

Trials with this intervention (10)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–10 of 10 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01228435	IPI-504 in NSCLC Patients With ALK Translocations	terminated	Phase 2	3	Massachusetts General HospitalOTHER	1	Dec 4, 2017	clinicaltrials
NCT00969917	Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma	withdrawn	Phase 2	0